Edition:
United Kingdom

Urogen Pharma Ltd (URGN.OQ)

URGN.OQ on NASDAQ Stock Exchange Global Market

64.99USD
18 May 2018
Change (% chg)

$2.95 (+4.76%)
Prev Close
$62.04
Open
$62.05
Day's High
$66.05
Day's Low
$62.05
Volume
34,577
Avg. Vol
50,723
52-wk High
$66.38
52-wk Low
$14.61

Chart for

About

Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for... (more)

Overall

Beta: --
Market Cap(Mil.): $381.96
Shares Outstanding(Mil.): 13.01
Dividend: --
Yield (%): --

Financials

  URGN.OQ Industry Sector
P/E (TTM): -- 84.06 32.75
EPS (TTM): -- -- --
ROI: -- 1.57 14.38
ROE: -- 2.43 16.07

BRIEF-Urogen Pharma Announces Positive Interim Results From Pivotal Phase 3 Olympus Trial Of UGN-101

* UROGEN PHARMA ANNOUNCES POSITIVE INTERIM RESULTS FROM PIVOTAL PHASE 3 OLYMPUS TRIAL OF UGN-101 (MITOGEL™) FOR NON-SURGICAL TREATMENT OF UPPER TRACT UROTHELIAL CANCER (UTUC)

21 May 2018

BRIEF-Urogen Pharma Reports Q4 Loss Per Share Of $0.74

* UROGEN REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

15 Mar 2018

BRIEF-Urogen Pharma Announces Pricing Of Public Offering Of Ordinary Shares

* UROGEN PHARMA ANNOUNCES PRICING OF PUBLIC OFFERING OF ORDINARY SHARES

19 Jan 2018

BRIEF-Urogen Announces Proposed Public Offering Of Ordinary Shares

* UROGEN PHARMA ANNOUNCES PROPOSED PUBLIC OFFERING OF ORDINARY SHARES

16 Jan 2018

Earnings vs. Estimates